Hypomethylating Agents (HMAs)

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Hypomethylating Agents (HMAs)

Jan 5, 2024, 17:36 | Insight

Talha Badar: What is the right duration of Venetoclax with HMA for AML?

Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, shared on X/Twitter:…

Dec 24, 2023, 18:42 | Insight

Naveen Pemmaraju: Important new paper led by Alex Bataller and Tapan Kadia

Naveen Pemmaraju shared on X/Twitter: "Important New paper just out in Blood Advances led by…

Nov 20, 2023, 04:08 | Insight

Adam C Palmer: You don’t need ‘1+1 makes 3’ if you can have ‘5+5 makes 10’

David Steensma, Chief Medical Officer at Ajax Therapeutics, and Anthony Letai, Professor at Dana-Farber Cancer…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023